A dedicated healthcare venture fund under Oceanpine Capital, Oceanpine Healthcare Fund (OHF) is focused on early stage companies in healthcare industries with disruptive and innovative technologies. We primarily invest in Chinese and US firms with core technologies and proprietary R&D capabilities. We bridge a supply and demand gap exacerbated by limited R&D in China. Our unique “Dual Market” strategy will help our portfolio companies with local resources and guidance, as well as providing diversification and value-realization for investors.
We have established extensive partnership with academic institutions in the USA, such as University of Chicago, MD Anderson Cancer Center, etc., to bring the research projects from these institutions to China and achieve successful transformation of technology.
Since our establishment, we have invested in a number of outstanding companies in both China and USA, including Human Longevity Inc. (Genome Technology), Edigene (Gene editing), Hua Dao Biotech (CAR-T), etc.